Cooley LLP’s Post

📣 Our CFO, Mert Zorlular, was recently featured in an article by Ana Mulero of BioSpace, discussing the trend of rising bankruptcies in the biotech sector. 💡 Mert shared his insights on why conventional business models are failing in today's environment. He explains, "The biotech industry as we know it today never had to operate under a high inflation/high yields kind of environment. Companies need creative ways to survive these challenging times." 📊 At Er-Kim, we've navigated the high-risk and high-inflation environments of international markets for 43 years, amassing considerable experience and developing a robust toolkit. 🌐 Thanks to our prudent financial management, robust treasury, and deep experience, we are proud to consistently deliver the latest medical innovations to the millions of patients we serve, no matter what challenges arise. #Biotech #Inflation #RiskManagement #ErKimPharmaceuticals #BioSpace #Finance #Pharmaceuticals

Newcourt Acquisition in a proxy filing called a Jan. 18 meetign for shareholders to vote on the proposed business combination with Psyence Bioscience. The deal values Psyence Biomedical at a pre-money equity value of $50 million.  A subsidiary of Psyence Group, the Toronto-based target is a clinical-stage life science biotechnology company developing uses for nature-derived psilocybin in mental health and wellbeing. At deal announcement a year ago, terms called for Psyence to receive a minimum of $20 million cash held in trust. Newcourt raised $220 million in an October 2021 IPO, although the account is now down to approximately $12.8 million as of Jan. 9, according to the proxy. Currently, the Newcourt sponsor owns approximately 84.8% of the SPAC’s outstanding shares.  https://lnkd.in/d_fEGTRH

SPAC Feed: Denali Capital Acquisition Outlines Longevity Biomedical Deal with Investor Presentation - https://lnkd.in/eNr_ceqg Denali Capital Acquisition filed an investor presentation highlighting its proposed combination with Longevity Biomedical at a pro forma equity valuation of… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic

Good article on potential M&A activity in the biopharma world. Few key points: 1. Top 25 biopharma are holding $1.37 trillion to be used for deal-making. 2. “Buyers were sitting on the sidelines because of lots of uncertainties around macroeconomics and regulatory issues…they cannot sit on the sideline too long, because the patent Cliff isn’t waiting for anybody.” 3. 34% of the dollar value of M&A deals by biopharmas last year covered oncology assets. #patentcliff #lossofexclusivity #firepower #drypowder

From investment banking to listing on the #Nasdaq, our Chief Financial Officer, Ozan Pamir, CFA, shares lessons he’s learned throughout his career in capital markets, including the particularities of pre-revenue funding, keeping an eye on cash burn, and how to compete for talent. Ozan’s expertise has been instrumental in propelling the success of 180 Life Sciences as we work towards developing therapeutics for inflammation, fibrosis, and pain. Read for more insight via StrategicCFO360 here: https://bit.ly/477eRyT #Biotech #Science #LifeSciences

SPAC Feed: London SPAC Ashington Agrees to $171.5M Deal with Biotech Firm - https://lnkd.in/ezWNkiNM London-listed Ashington Innovation has agreed to a reverse takeover with a biotech firm less than two months after floating with… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic

SPAC Feed: NKGen Biotech and Graf Acquisition Corp. IV Announce the … – GlobeNewswire - https://lnkd.in/gxWTBDjC NKGen Biotech and Graf Acquisition Corp. IV Announce the …  GlobeNewswire Source: NKGen Biotech and Graf Acquisition Corp. IV Announce the… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic

Blank-check company Vision Sensing Acquisition Corp. (NASDAQ: VSAC) Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd, a leading Korean biotechnology company. Mediforum will have a pre-money enterprise value of US$250 million at closing, and is also looking to secure additional financing in an amount up to US$50 million from private placement of equity, debt or other alternative financing. Norwich Capital Limited acts as the Lead Advisor for Mediforum. “Facilitating and coordinating this collaboration among the parties was no small feat. Despite the challenges posed by experiential differences and diverse origins, our collective commitment and strategic vision have triumphed. I commend the dedicated efforts of all parties involved”, said Jason Wong Kon Man, our Founder and CEO. Source: https://lnkd.in/diETDnsE #norwichhk #norwich #norwichcapital #spac #despac #ipo #nasdaq #nasdaqlisted #nyse #stockmarket #capitalmarkets #privateequity #fundraising #fundraiser #funding #invest #investing #investments

🚨The Most-Read M&A Deal Today: Jefferies and Goldman Sachs Confirm Advisory on GTCR LLC’s $627M Surmodics, Inc. Acquisition - Deal Summary Krugman Insights offers Reliable and Comprehensive Insights across M&A, Investment Banking, Private Equity, and Asset Management. 🔎 Financial Advisors on the Deal: Jefferies, Goldman Sachs 🔎 Legal Advisors on the Deal: Faegre Drinker, Kirkland & Ellis, Cleary Gottlieb Steen & Hamilton LLP 🔎 Key Stakeholders: GTCR LLC (Acquirer), Surmodics, Inc.. (Target) 💡 GTCR is set to acquire Surmodics, a leader in surface modification technologies for medical devices and in vitro diagnostics, for $627 million. Surmodics’ shareholders will receive $43 per share, a 41.1% premium over the 30-day average closing price. This acquisition promises immediate value for shareholders and positions Surmodics for future growth under GTCR's expertise. The transaction is expected to close in the second half of 2024, pending customary conditions, including shareholder and regulatory approvals. Post-acquisition, Surmodics will become a privately held company and delist from Nasdaq. ✅ TRY 30 DAYS FREE: https://lnkd.in/eBHYx37M ✅ FULL ARTICLE HERE: https://lnkd.in/eeu2GV5q #Jefferies #GoldmanSachs #GTCR #Surmodics #MergersAndAcquisitions #InvestmentBanking #CorporateFinance #HealthcareSector #StrategicPartnership #GlobalGrowth #FinancialAdvisory

More #biotech companies are pursuing various tracks as the path to move their innovations forward. During #JPM24 week, I spoke with Gabrielle Masson from Fierce Biotech to discuss the three tracks that biotechs are pursuing in search of growth: #IPO funding, #collaborations and #licensing and M&A. Learn more about how the industry is adapting to the new deal making landscape in the article. https://lnkd.in/ewZZCgGz